160 related articles for article (PubMed ID: 34148210)
1. Exploitation of nanocrystal suspension as an effective oral formulation for oxfendazole.
Sun Y; Chen D; Zhao Y; Zhou K; Zhang B; Wang H; Xie S
Drug Deliv Transl Res; 2022 May; 12(5):1219-1229. PubMed ID: 34148210
[TBL] [Abstract][Full Text] [Related]
2. Development of surface stabilized candesartan cilexetil nanocrystals with enhanced dissolution rate, permeation rate across CaCo-2, and oral bioavailability.
Jain S; Reddy VA; Arora S; Patel K
Drug Deliv Transl Res; 2016 Oct; 6(5):498-510. PubMed ID: 27129488
[TBL] [Abstract][Full Text] [Related]
3. Etoposide Amorphous Nanopowder for Improved Oral Bioavailability: Formulation Development, Optimization, in vitro and in vivo Evaluation.
Wang Y; Wang S; Xu Y; Wang P; Li S; Liu L; Liu M; Jin X
Int J Nanomedicine; 2020; 15():7601-7613. PubMed ID: 33116490
[TBL] [Abstract][Full Text] [Related]
4. Fabrication of Ibrutinib Nanosuspension by Quality by Design Approach: Intended for Enhanced Oral Bioavailability and Diminished Fast Fed Variability.
Rangaraj N; Pailla SR; Chowta P; Sampathi S
AAPS PharmSciTech; 2019 Oct; 20(8):326. PubMed ID: 31659558
[TBL] [Abstract][Full Text] [Related]
5. Formulation, optimization and in vitro-in vivo evaluation of febuxostat nanosuspension.
Ahuja BK; Jena SK; Paidi SK; Bagri S; Suresh S
Int J Pharm; 2015 Jan; 478(2):540-52. PubMed ID: 25490182
[TBL] [Abstract][Full Text] [Related]
6. Fabrication and characterization of glimepiride nanosuspension by ultrasonication-assisted precipitation for improvement of oral bioavailability and in vitro α-glucosidase inhibition.
Rahim H; Sadiq A; Khan S; Amin F; Ullah R; Shahat AA; Mahmood HM
Int J Nanomedicine; 2019; 14():6287-6296. PubMed ID: 31496686
[TBL] [Abstract][Full Text] [Related]
7. Enhanced Solubility and Dissolution Rate of Lacidipine Nanosuspension: Formulation Via Antisolvent Sonoprecipitation Technique and Optimization Using Box-Behnken Design.
Kassem MAA; ElMeshad AN; Fares AR
AAPS PharmSciTech; 2017 May; 18(4):983-996. PubMed ID: 27506564
[TBL] [Abstract][Full Text] [Related]
8. Development of an amorphous nanosuspension by sonoprecipitation-formulation and process optimization using design of experiment methodology.
Gajera BY; Shah DA; Dave RH
Int J Pharm; 2019 Mar; 559():348-359. PubMed ID: 30721724
[TBL] [Abstract][Full Text] [Related]
9. Effects of stabilizing agents on the development of myricetin nanosuspension and its characterization: an in vitro and in vivo evaluation.
Hong C; Dang Y; Lin G; Yao Y; Li G; Ji G; Shen H; Xie Y
Int J Pharm; 2014 Dec; 477(1-2):251-60. PubMed ID: 25445518
[TBL] [Abstract][Full Text] [Related]
10. Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations.
Sawant KK; Patel MH; Patel K
Drug Dev Ind Pharm; 2016; 42(5):758-68. PubMed ID: 26548349
[TBL] [Abstract][Full Text] [Related]
11. Chitosan-coated diacerein nanosuspensions as a platform for enhancing bioavailability and lowering side effects: preparation, characterization, and ex vivo/in vivo evaluation.
Allam AN; Hamdallah SI; Abdallah OY
Int J Nanomedicine; 2017; 12():4733-4745. PubMed ID: 28740381
[TBL] [Abstract][Full Text] [Related]
12. Characterization and evaluation in vivo of baicalin-nanocrystals prepared by an ultrasonic-homogenization-fluid bed drying method.
Shi-Ying J; Jin H; Shi-Xiao J; Qing-Yuan L; Jin-Xia B; Chen HG; Rui-Sheng L; Wei W; Hai-Long Y
Chin J Nat Med; 2014 Jan; 12(1):71-80. PubMed ID: 24484600
[TBL] [Abstract][Full Text] [Related]
13. Improved oral bioavailability for lutein by nanocrystal technology: formulation development, in vitro and in vivo evaluation.
Chang D; Ma Y; Cao G; Wang J; Zhang X; Feng J; Wang W
Artif Cells Nanomed Biotechnol; 2018 Aug; 46(5):1018-1024. PubMed ID: 28749189
[TBL] [Abstract][Full Text] [Related]
14. Enhanced biopharmaceutical performance of brick dust molecule nilotinib via stabilized amorphous nanosuspension using a facile acid-base neutralization approach.
Chougule M; Sirvi A; Saini V; Kashyap M; Sangamwar AT
Drug Deliv Transl Res; 2023 Oct; 13(10):2503-2519. PubMed ID: 37024611
[TBL] [Abstract][Full Text] [Related]
15. Investigation of nanosized crystalline form to improve the oral bioavailability of poorly water soluble cilostazol.
Miao X; Sun C; Jiang T; Zheng L; Wang T; Wang S
J Pharm Pharm Sci; 2011; 14(2):196-214. PubMed ID: 21733409
[TBL] [Abstract][Full Text] [Related]
16. Elucidating the particle size effect of andrographolide suspensions on their IVIVC performance in oral absorption.
Yao S; Chen N; Li M; Wang Q; Sun X; Feng X; Chen Y
Eur J Pharm Biopharm; 2022 Oct; 179():65-73. PubMed ID: 36058447
[TBL] [Abstract][Full Text] [Related]
17. Formulation and Evaluation of Naringenin Nanosuspensions for Bioavailability Enhancement.
Gera S; Talluri S; Rangaraj N; Sampathi S
AAPS PharmSciTech; 2017 Nov; 18(8):3151-3162. PubMed ID: 28534300
[TBL] [Abstract][Full Text] [Related]
18. Preparation, characterization and in vivo evaluation of amorphous tacrolimus nanosuspensions produced using CO2-assisted in situ nanoamorphization method.
Wang Y; Han X; Wang J; Wang Y
Int J Pharm; 2016 May; 505(1-2):35-41. PubMed ID: 27034003
[TBL] [Abstract][Full Text] [Related]
19. Enhanced dissolution rate and oral bioavailability of simvastatin nanocrystal prepared by sonoprecipitation.
Jiang T; Han N; Zhao B; Xie Y; Wang S
Drug Dev Ind Pharm; 2012 Oct; 38(10):1230-9. PubMed ID: 22229827
[TBL] [Abstract][Full Text] [Related]
20. Formulation, optimization, and in vitro-in vivo evaluation of olmesartan medoxomil nanocrystals.
Jain S; Patel K; Arora S; Reddy VA; Dora CP
Drug Deliv Transl Res; 2017 Apr; 7(2):292-303. PubMed ID: 28116656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
